Endothelial autophagy blockade fosters anti-cancer immunity

The discovery of immune checkpoints, consisting of transmembrane ligand-receptor protein pairs that negatively regulate the CD8 + T-cell-mediated immune response by antigen-presenting cells (APCs) and by cancer cells, has enabled a fundamental advancement of cancer therapies (Korman et al, 2022 ). I...

Full description

Saved in:
Bibliographic Details
Published in:EMBO molecular medicine 2024-01, Vol.16 (1), p.1-3
Main Authors: Villari, Giulia, Serini, Guido
Format: Article
Language:English
Subjects:
Biomedical and Life Sciences
Biomedicine
EMBO03
EMBO07
EMBO46
Molecular Medicine
News & Views
news-and-views
Views
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The discovery of immune checkpoints, consisting of transmembrane ligand-receptor protein pairs that negatively regulate the CD8 + T-cell-mediated immune response by antigen-presenting cells (APCs) and by cancer cells, has enabled a fundamental advancement of cancer therapies (Korman et al, 2022 ). Indeed, harnessing these homeostatic control mechanisms to their own advantage, tumor cells manage to defend themselves from the attack of the immune system, and immune checkpoint blockade (ICB) has proven to be an overwhelmingly successful antitumor therapeutic approach (Korman et al, 2022 ). G. Serini and G. Villari discuss the recent study by Verhoeven et al, in which autophagy is identified as a tumor vascular anti-inflammatory mechanism that impairs melanoma anti-tumor immunity.
ISSN:1757-4684
1757-4676
1757-4684
DOI:10.1038/s44321-023-00005-x